NA
TRDA icon

NewEdge Advisors’s Entrada Therapeutics TRDA Stock Holding History

NewEdge Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,167
Closed -$82.2K – 4375
2025
Q3 		$82.2K Buy
+14,167
New +$82.9K ﹤0.01% 2664

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's TRDA Position: Q4 2025 in Review

NewEdge Advisors sold out of Entrada Therapeutics (TRDA) in Q4 2025, closing a stake of 14,167 shares — an estimated $82.2K sold.

NewEdge Advisors first reported a position in TRDA in Q3 2025 and held it in 1 quarter. The position peaked at $82.2K in Q3 2025. 114 funds tracked by Wall St. Rank hold TRDA as of Q4 2025.

  • NewEdge Advisors reported no remaining Entrada Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 14,167 Entrada Therapeutics shares in Q4 2025, an estimated $82.2K.
  • NewEdge Advisors first reported a position in Entrada Therapeutics in Q3 2025 and held it in 1 quarter.
  • NewEdge Advisors's Entrada Therapeutics position peaked at $82.2K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.